Contrafect Corp (CFRX)

[BooDog]

Started accumulating.

CFRX Daily.


Interesting.
https://finance.yahoo.com/news/were-hedge-funds-contrafect-corp-022737097.html

ContraFect Corp (NASDAQ:CFRX) was in 18 hedge funds' portfolios at the end of the first quarter of 2021. The all time high for this statistic was previously 13. This means the bullish number of hedge fund positions in this stock currently sits at its all time high. CFRX investors should be aware of an increase in support from the world's most elite money managers lately. There were 10 hedge funds in our database with CFRX holdings at the end of December. Our calculations also showed that CFRX isn't among the 30 most popular stocks among hedge funds (click for Q1 rankings).

Why do we pay an

[BooDog]

Almost. eom

[BooDog]

Board marked. This puppy could get interesting.

[manysevens]

good stuff thank you for that read

this 4hr chart caught my eye today took a starter

[trickledownfacists]

ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office

[frugalNorwegian]

New site with Deep DD on CFRX: https://frugalnorwegian.com/cfrx/

- All information on 1 page
- Catalyst countdown timer
- several videos to watch
- provides a high level summary, and goes deep into the clinical trial success chances

Let me know what I can do to make the page better. Thanks!

[that_little_voice]

This sucks and it is annoying BUT, this is a great buy level. We will end up being victorious. The financing was ill timed and the banks leaked to funds who shorted and covered in the offering. Nothing has changed e4xcept we now have BARDA money, 80m in cash and futility study coming in a few quarters.

[trickledownfacists]

Going green

[trickledownfacists]

Checks off all the boxes to make a push higher. BARDA 88 million grant , US army 17 million dollar grant, fast track designation, Breakthrough designation, definitive phase two data, non dilutive funding, Big pharma takes stake (Pfizer 8%), and great leadership.

[trickledownfacists]

Maxim group just issued a $22PT

[lesgetrich]

PPS gapped up overnight on news of $86.8 million BARDA grant. PPS is now closing the gap. It should turn around somewhere near $6.35/share or sooner. We'll see.

[make it happen]

Numbers are extremely negative. Negative 8 digit cash flows in all ways. Negative profit, triple digit percent loss on equity and much more

Book Value Per Share (mrq) $0.66

Cash Flow Statement
Operating Cash Flow (ttm) -33.31M
Levered Free Cash Flow (ttm) -20.45M

Profitability
Profit Margin 0.00%
Operating Margin (ttm) 0.00%

Management Effectiveness
Return on Assets (ttm) -48.44%
Return on Equity (ttm) -283.93%

Gross Profit (ttm) -1.7M
EBITDA -29.84M
Net Income Avi to Common (ttm) -32.11M
Diluted EPS (ttm) -1.77

[trickledownfacists]

$CFRX Anyone think super bacteria was created and strengthened because of covid policy and actions....

CFRX just got $90M in non dilutive funding and have a PH3 finishing around the corner addressing just that.

HUGE.

[trickledownfacists]

Analysts PT’s range from $12.50-$25

[trickledownfacists]

$20PT

[Whalatane]

Who knows if this will “ run “ tomorrow ....probably not it’s “ running “ tonite ..... just my guess

Bottom line... CC tomorrow with more details , interim data in second half .... now with funds .. Fast tracked or Break through FDA designation

It’s a spec ... will live or die on the clinical trial results

Kiwi

[Roily23]

I guess I see it and my scan picked up at 6.55 and I see it ran to 9.25 in AH. Does it have room to run tomorrow or is this it?

[Roily23]

I know nothing and I really mean nothing about this symbol as this is my fisrt stop on the DD rail line. Well maybe the second as the first stop was a squeeze scan I ran and i see this up 25% today. Appreciate a little help on what I am looking at and I will be reading for myself in the meantime.

Thanks

[trickledownfacists]

Told ya. AH boooooom!

[trickledownfacists]

$CFRX - All March calls are up over 400%

[trickledownfacists]

Cup and handle now fully formed

[trickledownfacists]

$CFRX I'm back.

Deal worth over 50% of their MC made today.
No PR yet......!!!!!!!!!!!!!!!
Cash rich.
Data readout at 60% enrollment...
$PFE is a HUGE partner.
CUP AND HANDLE AT $6.50!
ANYDAY!

[Whalatane]

Good move today.
Congrats
Kiwi

[that_little_voice]

My company just got 86m in non dilutive funding from BARDA ( AS I SAID), what did CYDY GET AGAIN BESIDES THE MIDDLE FINGER AND A KICK IN THE REAR?

[that_little_voice]

people can't confirm it yet. Once it is out in a clear PR that gets circulated, I would assume we see an 8 handle. Between no more financing and BTD, we could see $30

[Gains2000]

and of course, the spike up to over $6.50 didn't seem to hold

[that_little_voice]

I agree. Trail is going slower hence the delay and adding more sites.

[Gains2000]

Interesting observation for what its worth from Clinicaltrials website:

The Phase 3 DISRUPT trial of Exebacase has 41 open trial Sites enrolling (Hospitals) in the U.S. currently. In the Phase 2 trial of Exebacase, there were 78 sites throughout the world of which 31 were in the U.S.

I realize that DISRUPT trial design involves only U.S. sites and there is a distinct advantage of this I e uniform standard of care. I just like that they have more sites open in the US which bodes well for enrollment to accelerate.

Having said this, management's silence likely means things are going slower cause of the pandemic. Hoping for some new guidance soon.

[Gains2000]

It definitely looks like this run is not real based on the declining pps. Its a shame really because if they would have gotten the BARDA grant, the stock would have popped and there would be no need for a dilution. With covid, we will also likely get a 2 Q delay for the interim look which makes a significant dilution assured. This, coupled with management's silence, makes for a shaky picture at least in the short term.

Having said this, I still think Exebacase is a game changer but a big BARDA grant (which they deserve) is not in the cards cause of the pandemic.

[HDGabor]

M-

I invested in ... and GTHX

You are welcome. Approved, AG close $37.48.

Best,
G

[that_little_voice]

Interesting moves the past few days. Could be the shorts covering as to not have another fiasco, rebalancing of the Russell or perhaps people are expecting something soon. Either way, this run won't be considered "real" unless it breaks 6.75 which has been the ceiling many times.

[MDEM]

Hi there HD Gabor,

In invested in AMRN and lost some, my mistake. Out of the rubbles I cames across two particularly noteworthy posters, you and D. Miller, I invested in SMSI and GTHX. I am looking at CFRX and some other names you wrote, doing my DD. Thank you for your advice.

Regards

MDEM

[Retiredceo]

I’m in a little....this morning. Should’ve gone all in!

[Whalatane]

Thx for the response

[that_little_voice]

They were granted BTD already.

Data was supposed to come at 60% futility which was supposed to be Q1 2021. I assume covid delayed them so Q3 2021.

[Whalatane]

Can either of you tell me when the interim analysis is due in the P3 trial and if this drug is designated Break Thru Therapy
Thx
Kiwi

[that_little_voice]

If you consider "5 YEAR OLD" AND "THICK SKULL" to be DEROGRATORY THEN YOU MY FRIEND IN FACT NEED THICKER SKIN.

I respond to your wild and inaccurate comments. Stop posting lies and I will stop proving you wrong.

[$5.95akadawson-m]

Let's see, so far you have been so derogatory:

I have a thick skull
I act like a five year old

Why are you still talking to me? Hmmm

[that_little_voice]

What? Now you are acting like a 5 year old. Are you saying Covid has always been CYDY focus? Stop it already.

Nader/Kelly saw the Covid train and went all in to get the buzz and PR while the initial HIV, GVHD and Cancer went in the trash can. They are no better than Barry Honig and Al Paladino during the crypto craze. Smart of them to fool people, get their share price up and do more debt while selling a massive amount of shares.

Lessons will be learned soon enough.

[$5.95akadawson-m]

No they haven't. That's your opinion. Because if they have "always focused" they wouldn't;t be where they are now.

"Again, some companies let the science speak."

[that_little_voice]

ContraFect has always focused on right side endo and bacterium infections. Done phase 1,2 and towards end of 3. CYDY now according to you is focusing on LH. What about 4 HIV BLA, cancer, gvhd M/M.

Again, some companies let the science speak. Others let jewelry store and faith authors speak non stop to inflate stock price.

[$5.95akadawson-m]

That is all true but my bet is on a drug to alleviate long haulers. CFRX has been touting for years and years with its promise. These two drug stocks may reach the finish line. I believe one thing, and you the other. We'll see who's is more correct.

[that_little_voice]

The difference here is 1 company plans to let the science speak and the other employs 20 PR firms . 1 gets invited to top conferences and the other does proactive videos. 1 has 86% institutional ownerships( including two investments from Pfizer) and 1 has .12%. 1 has never lost focus and continues with the same indication and 1 is on their 5th Hail Mary. 1 has $40m in cash and 1 needs to offer warrant discounts. 1 is on Nasdaq and 1 OTC. 1 has all star management and Board ( Sol Barer and Steve Gilman) and 1 has a jewelry store owner and someone who worked for SRPT 20 years ago. 1 has zero lawsuits and 1 has numerous from outside and insider lawsuits. 1 has no insider sales and 1 has several. 1 has received money from government several times and expecting BARDA $50-$100m inside of 3 months and 1 gets Fife toxic. 1 has a MC below $150Mc and 1 has over $3.5bln.



Yo are right, no comparison. You got the rabbit and I got the turtle.

[$5.95akadawson-m]

Let's talk facts. You want to compare two stocks: CFRX and CYDY. CYDY has generally been going up for the past three years and closed on Friday at 6.24. You know that Mrs. Kelly's wife bought CYDY three years ago for $.65 cents.

Now let's look at CFRX.

It so happens that I first bought the stock in May 2017 for $ 1.45 and I bought more too over a three year period.

1/18 - 1.32
2/18 - 1.90

1/19 - .59
1/22/20 - 1.14

2/4/20 - did a reverse split at 1-10

2/9/20 - 11.36
12/8/20 - 5.49 : when I sold this dog of bones and crap and during those three years, promises and more promises and yada yada

Friday it closed at what? $ 5.24!
Pfizer owns it and a host of others and it's down how far. Look how the shorts just drove it into oblivion after the reverse split. You're a person that knows about what shorts do and you're telling me that this stock is a great investment?

NO, I disagree and so does Chuckles.

[HDGabor]

Retiredceo,

Small market cap. Some cash on hand. Sniff of legitimacy on message boards. It’s like Amarin was when it was $1 lots of years ago.

Cash:

- September 30: $50.2 M vs June 30: $58.3 M ... a $8.1 M decrease (9 months was "net" $25.6 M decrease)
- It is enough for "6" quarter, till end of 2021. Meanwhile the interim analysis will have extra cost, the CF-370 R&D will be "less" as

CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to accelerating antibacterial research and development, is awarding the Company up to $18.9 million in additional non-dilutive capital to progress its second product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa (P. aeruginosa), in IND-enabling activities toward future Phase 1 clinical trials. This award provides initial funding of $4.9 million, and ContraFect could receive additional funding if certain project milestones are met. Any funding beyond the initial $4.9 million is at the sole discretion of CARB-X and subject to available funds.

and

it has entered into an initial funding agreement with the Cystic Fibrosis Foundation to investigate the potential utility of DLAs against resistant Gram-negative pathogens which afflict Cystic Fibrosis (CF) patients. The first stage of the agreement will profile funding for the in vitro activity of ContraFect’s next product candidate, CF-370, an engineered lysin targeting Pseudomonas aeruginosa, and amurin peptides, against bacterial specimens obtained from CF patients at different stages of disease.

... definitely enough till interim analyis.
- No question: they will raise cash the "next" day of the interim result (The last raise was in May ... $52.5 million, before deducting underwriting discounts and commissions and estimated offering expenses Public Offering and approximately $3.0 million in a private placement transaction with Pfizer

Legitimacy:

- Pfizer invested 2 times, owns app 4%
- "13F" shares were 15.665 M (56.33%) ... Top five owns app. the 38%
- Insiders own app. 5%
All together: 65+%

like Amarin: I am fine with $25+ in Q2 based on interim announcement

Best,
G

[that_little_voice]

On several public calls and presentations, Roger guided towards Q4 2020. Given the increase in Covid and working from home/skeleton staff, I assume things have been pushed out by a quarter or two. Remember, because this was said publicly, it is not a material event. There will have to be an 8K in either events. Nothing yet means it is still being worked on/considered. This is painful to park cash here for over a year watching this drift between $5 and $6 but think in two quarters we will know BARDA and futility analysis. With the low float outstanding, $20 sp is still under $500m MC with 70-130m in cash ( 50-100m grant with 30m left by end Q2) and Phase 3 study interim look.

[trickledownfacists]

Is there a timeline at all for that?

[that_little_voice]

Don't forget BARDA. $50-$100M in potential funding.

[that_little_voice]

Well they didn't hire 20 PR firms and boast about going from 3k to 43k share holders. Some executives let the science talk, some just promote.

[FINLI]

Waiting on all fronts... CVM, NWBO, CFRX.... all exciting but patience is being truly tested. All-in and no regrets. Cheers Finli